Literature DB >> 15339975

Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells.

James E Sidaway1, Robert G Davidson, Fergus McTaggart, Terry C Orton, Robert C Scott, Graham J Smith, Nigel J Brunskill.   

Abstract

Renal proximal tubule cells are responsible for the reabsorption of proteins that are present in the tubular lumen. This occurs by receptor-mediated endocytosis, a process that has a requirement for some GTP-binding proteins. Statins are inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase used for the therapeutic reduction of cholesterol-containing plasma lipoproteins. However, they can also reduce intracellular levels of isoprenoid pyrophosphates that are derived from the product of the enzyme, mevalonate, and are required for the prenylation and normal function of GTP-binding proteins. The hypothesis that inhibition of HMG-CoA reductase in renal proximal tubule cells could reduce receptor mediated-endocytosis was therefore tested. Five different statins inhibited the uptake of FITC-labeled albumin by the proximal tubule-derived opossum kidney cell line in a dose-dependent manner and in the absence of cytotoxicity. The reduction in albumin uptake was related to the degree of inhibition of HMG-CoA reductase. Simvastatin (e.g., statin) inhibited receptor-mediated endocytosis of both FITC-albumin and FITC-beta(2)-microglobulin to similar extents but without altering the binding of albumin to the cell surface. The effect on albumin endocytosis was prevented by mevalonate and by the isoprenoid geranylgeranyl pyrophosphate but not by cholesterol. Finally, evidence that the inhibitory effect of statins on endocytosis of proteins may be caused by reduced prenylation and thereby decreased function of one or more GTP-binding proteins is provided. These data establish the possibility in principle that inhibition of HMG-CoA reductase by statins in proximal tubule cells may reduce tubular protein reabsorption.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339975     DOI: 10.1097/01.ASN.0000138236.82706.EE

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  36 in total

1.  Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase.

Authors:  Wei Li; Yan Zhang; Richard Bouley; Ying Chen; Toshiyuki Matsuzaki; Paula Nunes; Udo Hasler; Dennis Brown; Hua A Jenny Lu
Journal:  Am J Physiol Renal Physiol       Date:  2011-04-20

Review 2.  Statins and proteinuria.

Authors:  Donald G Vidt
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 3.  Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins.

Authors:  Roberto Scarpioni; Marco Ricardi; Vittorio Albertazzi; Luigi Melfa
Journal:  World J Nephrol       Date:  2012-12-06

Review 4.  The proximal tubule and albuminuria: really!

Authors:  Landon E Dickson; Mark C Wagner; Ruben M Sandoval; Bruce A Molitoris
Journal:  J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 10.121

5.  Targeting the Trafficking of Kidney Water Channels for Therapeutic Benefit.

Authors:  Pui W Cheung; Richard Bouley; Dennis Brown
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-09-27       Impact factor: 13.820

6.  Chromatin Conformation Links Distal Target Genes to CKD Loci.

Authors:  Maarten M Brandt; Claartje A Meddens; Laura Louzao-Martinez; Noortje A M van den Dungen; Nico R Lansu; Edward E S Nieuwenhuis; Dirk J Duncker; Marianne C Verhaar; Jaap A Joles; Michal Mokry; Caroline Cheng
Journal:  J Am Soc Nephrol       Date:  2017-11-01       Impact factor: 10.121

7.  Host cell invasion by Staphylococcus aureus stimulates the shedding of microvesicles.

Authors:  Robin I DeWalt; Daniel A Petkovich; Ashley N Zahrt; Heather A Bruns; Susan A McDowell
Journal:  Biochem Biophys Res Commun       Date:  2013-02-11       Impact factor: 3.575

Review 8.  Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Authors:  Michael S Kostapanos; Christos V Rizos; Moses S Elisaf
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

Review 9.  Rosuvastatin in elderly patients.

Authors:  Michael H Davidson
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

10.  Albumin uptake in OK cells exposed to rotenone: a model for studying the effects of mitochondrial dysfunction on endocytosis in the proximal tubule?

Authors:  A M Hall; M Campanella; A Loesch; M R Duchen; R J Unwin
Journal:  Nephron Physiol       Date:  2010-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.